Pasithea Therapeutics Corp. (KTTAW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Los analistas estiman Beneficio por acción (EPS) de $-1.50 y ingresos de $0.00B para el próximo año fiscal.
Historial de Beneficio por acción (EPS): 2024: real $-12.69 vs est $-1.50 (no alcanzó -745.7%). 2025: real $-2.91 vs est $-0.68 (no alcanzó -327.9%). Precisión del analista: 18%.
